Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 564149, 12 pages
http://dx.doi.org/10.1155/2015/564149
Review Article

Influence of Two Common Polymorphisms in the EPHX1 Gene on Warfarin Maintenance Dosage: A Meta-Analysis

1Department of Pharmacy, Jining No. 1 People’s Hospital, Jining 272011, China
2Jining Hospital of Traditional Chinese Medicine, Jining 272137, China
3Jining Municipal Authority Hospital, Jining, Shandong 272000, China
4Department of Neurology, China-Japan Friendship Hospital, Yinghua Road No. 2, Chaoyang District, Beijing 100029, China

Received 29 April 2014; Revised 5 September 2014; Accepted 5 September 2014

Academic Editor: Roberto Cirocchi

Copyright © 2015 Hong-Qiang Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. S. Miller, S. M. Grandi, A. Shimony, K. B. Filion, and M. J. Eisenberg, “Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation,” The American Journal of Cardiology, vol. 110, no. 3, pp. 453–460, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. J. A. Heit, B. D. Lahr, T. M. Petterson, K. R. Bailey, A. A. Ashrani, and L. J. Melton III, “Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study,” Blood, vol. 118, no. 18, pp. 4992–4999, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. G. J. Hankey, M. R. Patel, S. R. Stevens et al., “Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF,” The Lancet Neurology, vol. 11, no. 4, pp. 315–322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. C. S. Wong, K. Batchelor, J. Bua, and F. Newall, “Safety and efficacy of warfarin in paediatric patients with prosthetic cardiac valves: a retrospective audit,” Thrombosis Research, vol. 128, no. 4, pp. 331–334, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. D. T. Le, R. T. Weibert, B. K. Sevilla, K. J. Donnelly, and S. I. Rapaport, “The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods,” Annals of Internal Medicine, vol. 120, no. 7, pp. 552–558, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Liang, Z. Chen, G. Guo et al., “Association of genetic polymorphisms with warfarin dose requirements in chinese patients,” Genetic Testing and Molecular Biomarkers, vol. 17, no. 12, pp. 932–936, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. D. Keeling, T. Baglin, C. Tait et al., “Guidelines on oral anticoagulation with warfarin—fourth edition,” British Journal of Haematology, vol. 154, no. 3, pp. 311–324, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. J. F. Carlquist and J. L. Anderson, “Using pharmacogenetics in real time to guide warfarin initiation: a clinician update,” Circulation, vol. 124, no. 23, pp. 2554–2559, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. T. T. Biss, A. J. Adamson, C. J. Seal, and F. Kamali, “The potential impact of dietary vitamin K status on anticoagulation control in children receiving warfarin,” Pediatric Hematology and Oncology, vol. 28, no. 5, pp. 425–427, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. E. Nutescu, I. Chuatrisorn, and E. Hellenbart, “Drug and dietary interactions of warfarin and novel oral anticoagulants: an update,” Journal of Thrombosis and Thrombolysis, vol. 31, no. 3, pp. 326–343, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. L. H. Cavallari, T. Y. Langaee, K. M. Momary et al., “Genetic and clinical predictors of warfarin dose requirements in African Americans,” Clinical Pharmacology and Therapeutics, vol. 87, no. 4, pp. 459–464, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. I. Y. Gong, R. G. Tirona, U. I. Schwarz et al., “Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy,” Blood, vol. 118, no. 11, pp. 3163–3171, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. J. F. Carlquist, B. D. Horne, C. Mower et al., “An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction,” Journal of Thrombosis and Thrombolysis, vol. 30, no. 3, pp. 358–364, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. E. Pautas, C. Moreau, I. Gouin-Thibault et al., “Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients,” Clinical Pharmacology and Therapeutics, vol. 87, no. 1, pp. 57–64, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. S. L. Chan, A. Thalamuthu, B. C. Goh et al., “Exon sequencing and association analysis of EPHX1 genetic variants with maintenance warfarin dose in a multiethnic Asian population,” Pharmacogenetics and Genomics, vol. 21, no. 1, pp. 35–41, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Zhao, J. Luo, and X. Cai, “Association between microsomal epoxide hydrolase 1 polymorphisms and susceptibility to esophageal cancer: a meta-analysis,” Tumor Biology, vol. 34, no. 4, pp. 2383–2388, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. H. Nisa, S. Budhathoki, M. Morita et al., “Microsomal epoxide hydrolase polymorphisms, cigarette smoking, and risk of colorectal cancer: the Fukuoka colorectal cancer study,” Molecular Carcinogenesis, vol. 52, no. 8, pp. 619–626, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. T. B. Tumer, G. Sahin, and E. Arinç, “Association between polymorphisms of EPHX1 and XRCC1 genes and the risk of childhood acute lymphoblastic leukemia,” Archives of Toxicology, vol. 86, no. 3, pp. 431–439, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. J. K. Hartsfield Jr., M. J. Sutcliffe, E. T. Everett, C. Hassett, C. J. Omiecinski, and J. A. Saari, “Assignment of microsomal epoxide hydrolase (EPHX1) to human chromosome 1q42.1 by in situ hybridization,” Cytogenetics and Cell Genetics, vol. 83, no. 1-2, pp. 44–45, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Özer, Y. Demirci, C. Hizel et al., “Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population,” Basic & Clinical Pharmacology & Toxicology, vol. 112, no. 3, pp. 209–214, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. C. Ciccacci, N. Paolillo, D. Di Fusco, G. Novelli, and P. Borgiani, “EPHX1 polymorphisms are not associated with warfarin response in an Italian population,” Clinical Pharmacology and Therapeutics, vol. 89, no. 6, p. 791, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. Q. Gu, Y. Kong, J. Schneede et al., “VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China,” European Journal of Clinical Pharmacology, vol. 66, no. 12, pp. 1217–1227, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. W.-W. Luo, H.-V. Zhang, S.-M. Ma, L.-H. Xu, Z.-X. Zhang, and X.-Q. Yang, “Effect of the epoxide hydrolase 1 gene polymerphism on warfarin dose,” Chinese Pharmaceutical Journal, vol. 45, no. 19, pp. 1489–1491, 2010. View at Google Scholar · View at Scopus
  24. G. Introcaso and G. Gesu, “Significance of consecutive international normalized ratio (INR) outcomes using statistical control rules in long-term anticoaguated patients. Optimitization of laboratory monitoring and interpretation of borderline measurements,” Clinical Chemistry and Laboratory Medicine, vol. 42, no. 3, pp. 294–299, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. A. Stang, “Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses,” European Journal of Epidemiology, vol. 25, no. 9, pp. 603–605, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. E. Zintzaras and J. P. A. Ioannidis, “HEGESMA: genome search meta-analysis and heterogeneity testing,” Bioinformatics, vol. 21, no. 18, pp. 3672–3673, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. E. Zintzaras and J. P. A. Ioannidis, “Heterogeneity testing in meta-analysis of genome searches,” Genetic Epidemiology, vol. 28, no. 2, pp. 123–137, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. J. L. Peters, A. J. Sutton, D. R. Jones, K. R. Abrams, and L. Rushton, “Comparison of two methods to detect publication bias in meta-analysis,” Journal of the American Medical Association, vol. 295, no. 6, pp. 676–680, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. S. C. Barbaux, S. Blankenberg, H. J. Rupprecht et al., “Association between P-selectin gene polymorphisms and soluble P-selectin levels and their relation to coronary artery disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 10, pp. 1668–1673, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. A. M. Carter, K. Anagnostopoulou, M. W. Mansfield, and P. J. Grant, “Soluble P-selectin levels, P-selectin polymorphisms and cardiovascular disease,” Journal of Thrombosis and Haemostasis, vol. 1, no. 8, pp. 1718–1723, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Elmas, P. Bugert, T. Popp et al., “The P-selectin gene polymorphism val168Met: a novel risk marker for the occurrence of primary ventricular fibrillation during acute myocardial infarction,” Journal of Cardiovascular Electrophysiology, vol. 21, no. 11, pp. 1260–1265, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. L. Ghazouani, N. Abboud, S. B. Khalifa et al., “Contribution of SELP and PSGL-1 genotypes and haplotypes to the presence of coronary heart disease in Tunisians,” Molecular Biology Reports, vol. 38, no. 1, pp. 495–501, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. C. L. Liao, M. Z. Huang, H. Y. Liu, D. Liang, and G. Z. Pam, “Association of the genotype and serum level of P-selectin with acute myocardial infarction,” Chinese Journal of Arteriosclerosis, vol. 19, pp. 151–154, 2011. View at Google Scholar
  34. F. Kee, G. F. Baxter, C. Morrison et al., “Polymorphisms of the P-selectin gene and risk of myocardial infarction in men and women in the ECTIM extension study,” Heart, vol. 84, no. 5, pp. 548–552, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. C. L. Liao, M. Z. Huang, H. Y. Liu, D. Liang, and G. Z. Pan, “Association P-selectin gene polymorphisms and haplotype with coronary heart disease,” Journal of Guangxi Medical University, vol. 29, pp. 598–600, 2012. View at Google Scholar
  36. S. A. Rosner, P. M. Ridker, R. Y. L. Zee, and N. R. Cook, “Interaction between inflammation-related gene polymorphisms and cigarette smoking on the risk of myocardial infarction in the Physician's Health Study,” Human Genetics, vol. 118, no. 2, pp. 287–294, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. K. A. Volcik, C. M. Ballantyne, J. Coresh, A. R. Folsom, K. K. Wu, and E. Boerwinkle, “P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14 595 participants: the Atherosclerosis Risk in Communities Study,” Atherosclerosis, vol. 186, no. 1, pp. 74–79, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. S. W. Huang, D. K. Xiang, B. L. Chen, L. Huang, B. Q. An, and G. F. Li, “Correlation between EPHX1 polymorphism and Warfarin maintenance dosage,” Tianjin Medical Journal, vol. 39, pp. 887–889, 2011. View at Google Scholar
  39. B. Dahlbäck, “Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases,” Journal of Internal Medicine, vol. 257, no. 3, pp. 209–223, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. M. Wadelius and M. Pirmohamed, “Pharmacogenetics of warfarin: current status and future challenges,” Pharmacogenomics Journal, vol. 7, no. 2, pp. 99–111, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. J. Oldenburg, M. Marinova, C. Müller-Reible, and M. Watzka, “The vitamin K cycle,” Vitamins and Hormones, vol. 78, pp. 35–62, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. R. Loebstein, M. Vecsler, D. Kurnik et al., “Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9,” Clinical Pharmacology & Therapeutics, vol. 77, no. 5, pp. 365–372, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. M. Vecsler, R. Loebstein, S. Almog et al., “Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin,” Thrombosis and Haemostasis, vol. 95, no. 2, pp. 205–211, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Wadelius, L. Y. Chen, N. Eriksson et al., “Association of warfarin dose with genes involved in its action and metabolism,” Human Genetics, vol. 121, no. 1, pp. 23–34, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. M. T. Lee, C. H. Chen, C. H. Chou et al., “Genetic determinants of warfarin dosing in the Han-Chinese population,” Pharmacogenomics, vol. 10, pp. 1905–1913, 2009. View at Google Scholar
  46. M. S. M. Issac, M. S. El-Nahid, and M. Y. Wissa, “Is there a role for MDR1, EPHX1 and Protein Z gene variants in modulation of warfarin dosage? A study on a cohort of the egyptian population,” Molecular Diagnosis and Therapy, vol. 18, no. 1, pp. 73–83, 2014. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus